Table
1: Patient characteristics. Characteristics of study
population (n=221) male 70.1%.
|
mean |
SD |
median |
IQR |
||
|
Demographics |
|||||
|
age |
47.82 |
14.55 |
46 |
18 |
|
|
EF (Echo) |
% |
34.99 |
13.81 |
32.0 |
20 |
|
BMI |
kg/m² |
27.07 |
4.79 |
25.29 |
5.43 |
|
n (%) |
|||||
|
Hypertension |
83 (37.6) |
||||
|
non obstr. CAD |
28 (12.7) |
||||
|
Atrial fibrillation |
21 (9.5) |
||||
|
NYHA-FC I |
70 (31) |
||||
|
NYHA-FC II |
98 (44) |
||||
|
NYHA-FC III + IV |
51 (25) |
||||
|
Medication |
|||||
|
ACE-Inhibitors / Angiotensin Receptor
Blockers |
178 (81.7) |
||||
|
Betablockers |
165 (74.7) |
||||
|
Mineral Receptor Antagonists |
73 (33) |
||||
|
Diuretics |
116 (52.5) |
||||
|
Hemodynamics |
|||||
|
CO |
L/min |
4.20 |
1.24 |
4.1 |
1.6 |
|
PCWP |
mmHg |
17.71 |
8.62 |
16.0 |
13 |
|
mPAP |
mmHg |
27.21 |
10.66 |
25.0 |
14 |
|
mRAP |
mmHg |
10.11 |
4.82 |
9.0 |
6 |
|
Laboratory |
|||||
|
Hb |
g/dl |
14.52 |
1.58 |
14.7 |
0.17 |
|
hsCRP |
mg/L |
0.68 |
1.80 |
0.19 |
0.44 |
|
ct-FGF23 |
RU/ml |
46.72 |
100.34 |
16.83 |
30.93 |
|
Creatinin |
mg/dl |
0.96 |
0.21 |
0.91 |
0.29 |
|
eGFR |
ml/min/1.73m² |
118.32 |
37.22 |
116.70 |
43.76 |
|
Phosphate |
mg/dl |
3.34 |
0.64 |
3.41 |
0.80 |
|
Calcium |
mg/dl |
2.31 |
0.14 |
2.31 |
0.26 |
|
Parathormon |
ng/L |
41.08 |
42.16 |
32.75 |
21.47 |
|
Vit-D3 |
nmol |
50.30 |
26.67 |
47.8 |
35.9 |
|
gGT |
U/dl |
71.60 |
80.87 |
44.0 |
56.0 |
|
NTproBNP
|
ng/l |
1965 |
3602 |
921 |
2014 |
|
Ferritin (n=104) |
µmol/L |
181.66 |
184.95 |
123.0 |
67.0 |
|
Iron (n=104) |
µg/L |
17.23 |
9.30 |
16.0 |
11.0 |
ACE-I- Angiotensin converting enzyme inhibitor; BMI- body mass index;
PCWP- pulmonary capillary wedge pressure; CO- cardiac output; mRAP- mean right
atrial pressure; mPAP- mean pulmonary aterial pressure; Hb- hemoglobin; hsCRP-
high sensitie C-reactive protein; eGFR- estimated glomerular filtration rate;
NTproBNP- N-terminal pro brain natrium peptide; Vit-D3- 25-hydroxy vitamin D3;
gGT- γ-glutamyl
transferase; ct-FGF23- C- terminal fibrosing growth factor 23.